


Patent Docket PL154R2

S. J. G. Ande
10/6
Kunda
4/24/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of Goddard et al. Serial No.: 09/202,054 Filed: December 7, 1998 For: Human Toll Homologues	Group Art Unit: 1644 Examiner: M. Tung CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on April 4, 2001  Diane L. Marschang
--	--

RESPONSE TO NOTICE TO COMPLY AND PRELIMINARY AMENDMENT

BOX SEQUENCE
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Responsive to the Notice to Comply mailed February 27, 2001, please enter the following amendment.

In the Specification:

On page 7, in the paragraph appearing on lines 8-23, please amend the text to read as follows:

--- Figure 7 Domain function of TLR2 in signaling. a. Illustrations of various TLR2 constructs. TLR2-WT, the full-length epitope-tagged form of TLR2, TLR2-Δ1 and -Δ2 represent a truncation of 13 or 141 amino acids at the carboxyl terminus, respectively. CD4-TLR2, a human CD4-TLR2 chimera replacing the extracellular domain of TLR2 with amino acids 1-205 of human CD4. ECD, extracellular domain; TM, transmembrane region; ICD, intracellular domain. b. C-terminal residues critical for IL-1R (SEQ ID NO:31) and TLR2 (SEQ ID NO:32) signal transduction. Residue numbers are shown to the right of each protein. Arrow indicated the position of the TLR2-Δ1 truncation. *, residues essential for IL-1R signaling (Heguy *et al.*, *J. Biol. Chem.* 267, 2605-2609 [1992]; Croston *et al.*, *J. Biol. Chem.* 270, 16514-16517 [1995]) I I, identical amino acid; :, conservative changes. c. TLR-R2 variants fail to induce NF-κB in response to LPS and LBP. 293 cells were transiently transfected with pGL3.ELAM.tk and expression vectors encoding full-length TLR2 or TLR2 variants as indicated. The cells were also transfected with a CD14 expression plasmid (+mCD14) or with a control plasmid (-mCD14). Equal expression of each protein is confirmed by Western blot using either anti-gD or CD4 antibody (bottom).